| Ytd | 382.02% | |
| 1y | 399.55% |
| Open | 5.58 | Prev Close | 5.58 | Low | 5.40 | High | 5.64 | Mkt Cap | 207.17M |
| Vol | 65.38K | Avg Vol | 286.27K | EPS | -1.05 | P/E | N/A | Forward P/E | -1.17 |
| Beta | -0.99 | Short Ratio | 0.82 | Inst. Own | 52.31% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 5.24 | 200-d Avg | 3.27 | 1yr Est | 2.67 |
ANTX News
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biophar
The Russell 2000 hits a record high as small caps outperform the Nasdaq 100, led by three companies,
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.18) per share which beat the analyst
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the dis
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biophar
NEW YORK, July 20, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating A
Guggenheim analyst Brad Canino initiates coverage on AN2 Therapeutics (NASDAQ:ANTX) with a Buy ra
Gainers Pulsenmore (NASDAQ:PLSM) stock increased by 152.0% to $8.59 during Wednesday's pre-mark
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Bioscienc
AN2 Therapeutics, Inc. (NASDAQ:ANTX) a clinical-stage biopharmaceutical company developing novel sma
Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally in
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX) a clinical-stage biopharm
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical comp
Leerink Partners analyst Joseph Schwartz upgrades AN2 Therapeutics (NASDAQ:ANTX) from Market Perf
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biophar
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical comp
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company developing novel sm
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biophar
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.29) per share which missed the analy
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biophar
AN2 Therapeutics Inc. (NASDAQ: ANTX) shares were down during Wednesday's premarket session in a vola
AN2 Therapeutics stock dips in premarket after a 90% surge tied to a $40 million equity raise.
AN2 Therapeutics Inc (NASDAQ: ANTX) shares are surging Monday afternoon after the clinical-stage bio
AN2 Therapeutics Inc (NASDAQ: ANTX) shares are surging Monday afternoon after the company announced
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biophar
Substantial clinical evidence provides rationale to initiate Phase 2 study in PVPhase 2 study expect
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biophar
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical comp
AN2 aims to advance oral treatment option for patients currently reliant on complex, off-label IV th
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical comp
AN2 Therapeutics (ANTX) might move higher on growing optimism about its earnings prospects, which is
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.31) per share which missed the analy
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical comp
AN2 awarded third year of funding from Gates FoundationAN2 Therapeutics, Inc. (NASDAQ:ANTX), a bioph
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical comp
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.21) per share which beat the analyst
Study highlights high mortality despite standard of care and provides critical data to optimize desi
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.35) per share which missed the analy
JMP Securities analyst Roy Buchanan maintains AN2 Therapeutics (NASDAQ:ANTX) with a Market Outper
EBO-301 truncated Phase 3 study (n=97) misses primary endpoint; results unable to confirm clinical e
Citizens Capital Markets analyst Roy Buchanan reiterates AN2 Therapeutics (NASDAQ:ANTX) with a Ma
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.25) per share which beat the analyst